Mechanism
No discrete molecular receptor identified; proprietary donor-derived
Assets acting on this target.
- Class
- Allogeneic, non-genetically modified leukocyte cell therapy (Second Life Therapeutics' "Universal Receptive System" platform)
- Pathway
- Proprietary ex vivo activation of donor leukocytes to modulate anti-tumor immune cell activity
- Notes
- original target text: No discrete molecular receptor identified; proprietary donor-derived leukocyte platform
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.